Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
South Korean biotech company Celltrion Inc. plans to merge with its two affiliates, Celltrion Healthcare Co. and Celltrion Pharma Inc., to establish a holding company structure by the end of 2021.
Celltrion Group Chairman Seo Jung-jin would establish Celltrion Healthcare Holdings by investing his stakes in Celltrion Healthcare, making the holding company its largest shareholder.
Celltrion Group Chairman Seo Jung-Jin would hold 11.21 percent in Celltrion Healthcare Holdings, which in turn would have a 24.33 percent stake.
The process would be hastened when requirements for relevant laws regarding anti-monopoly and fair trade are met.
Seo noted that the merger would depend upon the wishes of shareholders.
Celltrion is conducting phase one clinical trials on patients of its coronavirus treatment, CT-P59, to evaluate the safety and efficacy of the treatment.
